- |||||||||| Hemlibra (emicizumab-kxwh) / Roche, Obizur (susoctocog alfa) / Takeda, Ipsen
SUCCESSFUL HEMODIALYSIS INITIATION IN ACQUIRED HEMOPHILIA A MANAGED WITH SUSOCTOCOG ALFA AND EMICIZUMAB (Exhibition Hall/Poster Board No. P491) - Mar 19, 2026 - Abstract #ISNWCN2026ISN_WCN_2187;
To our knowledge, this is the first report documenting HD initiation and maintenance in AHA using the sequential susoctocog alfa followed by emicizumab. This case highlights an infection-conscious practical strategy for frail patients-prioritizing rapid procedural hemostasis with rpFVIII when rFVIIa response is inadequate, followed by emicizumab prophylaxis to sustain bleed prevention and minimize steroid or IST exposure.
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, NovoSeven (eptacog alfa) / Novo Nordisk, Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz
When Oxygen Turns Red: Diffuse Alveolar Hemorrhage During Induction Therapy for Secondary Acute Myeloid Leukemia (Area B, Halls WA2-WA3 (Level II, OCCC West Concourse); Poster Board # P235) - Mar 3, 2026 - Abstract #ATS2026ATS_2015;
This case underscores the importance of early recognition and prompt, multidisciplinary intervention in DAH during AML induction therapy. Time sensitive management, guided by understanding the underlying pathophysiology, can transform a potentially fatal event into a story of remission and recovery.
- |||||||||| Sevenfact (eptacog beta activated) / LFB SA, HEMA Biologics, NovoSeven (eptacog alfa) / Novo Nordisk
Retrospective data, Journal, Real-world evidence: Real World Experience with use of Coagulation Factor VIIa at an Academic Medical Center. (Pubmed Central) - Dec 11, 2025
Cost avoidance was estimated at $554,400 over a 12-month period.ConclusionWe treated a small cohort of patients with eptacog beta without adverse outcomes. Other hospitals might evaluate their rFVIIa use and consider opportunities for substitution.
- |||||||||| NovoSeven (eptacog alfa) / Novo Nordisk, Obizur (susoctocog alfa) / Takeda, Ipsen, Rituxan (rituximab) / Roche
Unexplained bleeding and a hidden inhibitor: A case of late-onset acquired hemophilia A () - Dec 5, 2025 - Abstract #ASH2025ASH_8559;
AHA should be considered in elderly patients with unexplained bleeding and isolated prolonged aPTT, even following trauma. Increased awareness and timely intervention can significantly improve outcomes in this rare but potentially fatal disorder.
- |||||||||| Sevenfact (eptacog beta activated) / LFB SA, HEMA Biologics, NovoSeven (eptacog alfa) / Novo Nordisk
Journal, Real-world evidence: Real-World Experience with Eptacog Beta for On-Label and Off-Label Indications: The Spanish Experience. (Pubmed Central) - Nov 27, 2025
Our experience provides further evidence of the efficacy and safety of eptacog beta for surgical prophylaxis and treatment of bleeding in patients with haemophilia A with inhibitors, but also in those with factor VII deficiency. To our knowledge, this is the first report to describe the use of eptacog beta for factor VII deficiency and acquired haemophilia.
- |||||||||| tranexamic acid oral / Generic mfg., NovoSeven (eptacog alfa) / Novo Nordisk
Journal: Recombinant Factor VIIa Prophylaxis in 2 Brothers with Bernard-Soulier Syndrome. (Pubmed Central) - Nov 19, 2025
Recombinant activated factor VIIa (rFVIIa, trade name: NovoSeven) has emerged as a potential alternative therapy...The older brother, aged 19, presented with persistent gingival bleeding that was unresponsive to tranexamic acid and required hospital-based interventions, including platelet transfusions...This case highlights the potential role of rFVIIa as a viable alternative to platelet transfusions in patients with recurrent bleeding. Further studies are needed to establish standardized protocols for prophylactic rFVIIa use in BSS.
- |||||||||| Kcentra (plasma-derived prothrombin complex concentrate) / CSL Behring, Feiba (anti-inhibitor coagulant complex) / Takeda
Evaluating reversal strategies for long-acting factor XI antibodies: RFVIIa (OCCC - West Halls B3-B4) - Nov 4, 2025 - Abstract #ASH2025ASH_8154;
BAY1831865), and theactive site binding FXIa inhibitor osocimab...With contact activation (ellagic acid or kaolin), the relative potency of thrombin inhibitionshifted: AB011 again showed the strongest inhibition on par with FXI-/- plasma, followed by gruticibart,and osocimab... FXI inhibitors produce anticoagulant effects across global coagulation assays that can bepartially or completely reversed by bypassing agents, particularly NovoSeven
- |||||||||| NovoSeven (eptacog alfa) / Novo Nordisk
The Mayo Clinic enterprise experience and outcomes of perioperative utilization of recombinant factor VIIa (rFVIIa, NovoSeven (OCCC - West Halls B3-B4) - Nov 4, 2025 - Abstract #ASH2025ASH_7461;
Postoperative thrombotic events were rare, while ISTH-defined bleeding complications and readmissions were common. Most bleeding complications wereminor, but their frequency was highest in the early postoperative period and again beyond one year.High-risk surgeries were associated with greater blood loss, prolonged hospitalization, and a higherburden of postoperative complications.
- |||||||||| Hemlibra (emicizumab-kxwh) / Roche, NovoSeven (eptacog alfa) / Novo Nordisk, Rituxan (rituximab) / Roche
Acquired Hemophilia A (AHA) associated with monoclonal gammopathy: A single institution case series (OCCC - West Halls B3-B4) - Nov 4, 2025 - Abstract #ASH2025ASH_4796;
This suggests that even minimal clonal plasma cell activity,characteristic of MGUS, can cause significant immune dysregulation leading to severe autoimmunecomplications like AHA.Although MGUS typically requires no treatment, persistent or refractory bleeding with sustained inhibitorlevels may warrant myeloma directed therapy targeting the plasma cell clone. Hence further awarenessabout of this novel association could also inform the treatment strategies in patients not responding toinitial measures.
- |||||||||| Kcentra (plasma-derived prothrombin complex concentrate) / CSL Behring, NovoSeven (eptacog alfa) / Novo Nordisk
Anesthetic Management of a PVC Ablation Complicated by Pericardial Tamponade and Subsequent Embolic Stroke (Monitor 1; Exhibit Hall, Street Level) - Aug 19, 2025 - Abstract #ASA2025ASA_3392;
Given persistent neurological decline, extubation was delayed, prompting neuroimaging that revealed multiple acute strokes. Multimodal resuscitation and coagulation management were critical in stabilizing this patient for postoperative neurological assessment.
- |||||||||| NovoSeven (eptacog alfa) / Novo Nordisk
Electroconvulsive Therapy (ECT) for a Patient with Hemophilia A (Monitor 8; Exhibit Hall, Street Level) - Aug 19, 2025 - Abstract #ASA2025ASA_2657;
To decrease bleeding risk, hematology service recommended NovoSeven (recombinant Factor VIIa) 1 mg IV 10-15 minutes prior to each ECT session. Anesthetic considerations and successful management of patients with life-threatening coagulopathy requiring ECT are discussed.
- |||||||||| Kcentra (plasma-derived prothrombin complex concentrate) / CSL Behring, NovoSeven (eptacog alfa) / Novo Nordisk
Anesthetic Management of a PVC Ablation Complicated by Pericardial Tamponade and Subsequent Embolic Stroke (Monitor 1; Exhibit Hall, Street Level) - Aug 13, 2025 - Abstract #ASA2025ASA_3392;
Given persistent neurological decline, extubation was delayed, prompting neuroimaging that revealed multiple acute strokes. Multimodal resuscitation and coagulation management were critical in stabilizing this patient for postoperative neurological assessment.
- |||||||||| NovoSeven (eptacog alfa) / Novo Nordisk
Electroconvulsive Therapy (ECT) for a Patient with Hemophilia A (Monitor 8; Exhibit Hall, Street Level) - Aug 13, 2025 - Abstract #ASA2025ASA_2657;
To decrease bleeding risk, hematology service recommended NovoSeven (recombinant Factor VIIa) 1 mg IV 10-15 minutes prior to each ECT session. Anesthetic considerations and successful management of patients with life-threatening coagulopathy requiring ECT are discussed.
- |||||||||| NovoSeven (eptacog alfa) / Novo Nordisk, Rituxan (rituximab) / Roche
A TARDY PRESENTATION OF ACQUIRED HEMOPHILIA A (McCormick Place - Lakeside Center Exhibit Hall Poster Area 3) - Jun 30, 2025 - Abstract #CHEST2025CHEST_2654;
Novoseven was infused at 4000mcg (70-90 mcg/kg/dose) every 2-3 hours until bleeding was controlled in adjunct with methylprednisolone 125mg and eventual oral prednisone 40mg taper...Subsequent weekly immunosuppressant therapy (IST) with Rituximab, a chimeric monoclonal antibody targeting the autoimmune mediated inhibitors, was initiated for a total of 8 weeks... Although incidence in an advanced age group is low [1], AHA requires prompt testing, diagnosis, treatment and avoidance of triggering or inciting events of bleeding.
- |||||||||| NovoSeven (eptacog alfa) / Novo Nordisk, Rituxan (rituximab) / Roche
Journal: Inhibitor Eradication in Postpartum Acquired Haemophilia A: Real-Life Case Series and Literature Review. (Pubmed Central) - Jun 18, 2025
Although incidence in an advanced age group is low [1], AHA requires prompt testing, diagnosis, treatment and avoidance of triggering or inciting events of bleeding. Notwithstanding that postpartum AHA has been reported to have a high rate of spontaneous remission, nearly half of this series experienced inhibitor eradication more than 1 month after disease onset and using immunosuppressive treatment for more than 2 months, with additional drugs being used in more than 40% of them, thus showing difficulties in disease remission in this postpartum AHA subpopulation.
- |||||||||| Hemlibra (emicizumab-kxwh) / Roche
Enrollment open: WILL-EMI: A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease (clinicaltrials.gov) - Jun 12, 2025
P3, N=66, Recruiting,
Notwithstanding that postpartum AHA has been reported to have a high rate of spontaneous remission, nearly half of this series experienced inhibitor eradication more than 1 month after disease onset and using immunosuppressive treatment for more than 2 months, with additional drugs being used in more than 40% of them, thus showing difficulties in disease remission in this postpartum AHA subpopulation. Not yet recruiting --> Recruiting
- |||||||||| NovoSeven (eptacog alfa) / Novo Nordisk
GLANZMANN THROMBASTHENIA AND VENOUS THROMBOSIS : ABOUT 2 CASES () - May 15, 2025 - Abstract #EHA2025EHA_4463;
The use of unfractionated heparin and low-molecular-weight heparin in the 1st case remains the treatment of choice while the role of new oral anticoagulants is increasingly discussed. The use of Vena caval filters is a solution in the second case for the prevention of pulmonary embolism.
- |||||||||| NovoSeven (eptacog alfa) / Novo Nordisk
COAGULATION FACTOR DEFICIENCIES: AN OVERVIEW OF A SINGLE CENTER () - May 15, 2025 - Abstract #EHA2025EHA_3670;
Coagulation factor deficiencies represent a diverse group of bleeding disorders with varying clinical manifestations depending on the factor involved. Understanding the biological and clinical features, and management of these conditions is crucial for effective diagnosis and treatment.
- |||||||||| NovoSeven (eptacog alfa) / Novo Nordisk
Antihypertensive therapy and emergent management for acute intracerebral hemorrhage (Venue 04 (Osaka International Convention Center 10F Conference Rooms 1001-1002)) - May 8, 2025 - Abstract #JSNE2025JSNE_2034;
Aims: Phase I (TQG203-I-01) and Phase III (TQG203-III-01) studies were designed to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety of TQG203 in patients with congenital hemophilia A or B. The TQG203-I-01 study assessed the pharmacokinetics and pharmacodynamics (PK/PD) of TQG203 in hemophilia patients with inhibitors, comparing it to Novoseven On the other hand, recombinant activated factor VII (rFVIIa, NovoSeven
- |||||||||| Sevenfact (eptacog beta activated) / LFB SA, HEMA Biologics, NovoSeven (eptacog alfa) / Novo Nordisk
Review, Journal: Recombinant factor VIIa: new insights into the mechanism of action through product innovation. (Pubmed Central) - Feb 24, 2025
Further research is required to assess the clinical relevance of these differences. A better understanding of the mechanisms by which rFVIIa promotes hemostasis in patients will provide insights when evaluating clinical outcomes of safety and efficacy for innovative bypassing therapies.
- |||||||||| Sevenfact (eptacog beta activated) / LFB SA, HEMA Biologics
Journal, Real-world evidence, Real-world effectiveness, Real-world: Real-world effectiveness of eptacog beta in patients with haemophilia and inhibitors: A multi-institutional case series. (Pubmed Central) - Dec 20, 2024
A better understanding of the mechanisms by which rFVIIa promotes hemostasis in patients will provide insights when evaluating clinical outcomes of safety and efficacy for innovative bypassing therapies. In this case series, eptacog beta was safe, effective, and economical as first-line therapy, treatment of refractory BEs, management of perioperative bleeding, or prophylaxis in haemophilia patients with inhibitors.
- |||||||||| The Influence of Coagulation Factor Biosimilars in Shortening the Activated Partial Thromboplastin Time in Patients with Hemophilia a () - Dec 7, 2024 - Abstract #ASH2024ASH_7560;
Negative correlation was observed between PT and FVII values after adding Kogenate FS (r=-0.103, p<0.001), aPTT and FVIII values after adding Kogenate FS (r=-0.898, p<0.001), aPTT and FVIII values after adding NovoEight (r=-0.865, p<0.001), as well as aPTT and FVIII values after adding AryoSeven (r=-0.647, p<0.001).Conclusion : All the investigated drugs significantly shorten aPTT values and increase values of FVIII and FVII. In terms of efficacy, no difference exists between AryoSeven and NovoSeven, as well as between Kogenate FS and NovoEight only in altering PT.
- |||||||||| Review, Journal: Acquired haemophilia: Update in 2024 (Pubmed Central) - Nov 13, 2024
Eradication of inhibitor should be established as soon as the diagnosis is confirmed with steroid alone often associated with cytotoxic agents or rituximab, depending on FVIII activity and inhibitor titer. The purpose of this review is to summarize the epidemiology, etiopathogenesis, diagnosis, treatment of AHA and discuss current recommendations.
- |||||||||| Humate-P (human plasma derived von Willebrand factor/FVIII complex) / CSL Behring, NovoSeven (eptacog alfa) / Novo Nordisk
Labor Epidural in Patient with Von Willebrand Disease and Factor VII Deficiency (Exhibit Hall) - Aug 6, 2024 - Abstract #ASA2024ASA_4181;
Postpartum, von Willebrand factor activity (targeting >50% with Humate-P) and Factor VII activity (targeting >20% with NovoSeven) were trended, and she received peripartum tranexamic acid. This case highlights obstetric, anesthetic, and ethical challenges that inherited bleeding disorders carry.
- |||||||||| Comirnaty (tozinameran) / Pfizer, BioNTech, NovoSeven (eptacog alfa) / Novo Nordisk
Review, Journal: Severe acquired hemophilia A associated with COVID-19 vaccination: A case report and literature review. (Pubmed Central) - Aug 2, 2024
Although the benefits outweigh the risks of vaccination, AHA should be considered in the differential diagnosis of unusual bleeding following the vaccinations. Early diagnosis and management before severe bleeding are critical for successfully controlling life-threatening bleeding.
- |||||||||| NovoSeven (eptacog alfa) / Novo Nordisk
Review, Journal: Current status and future prospects of activated recombinant coagulation factor VIIa, NovoSeven (Pubmed Central) - Jul 28, 2024
Emerging non-factor therapies such as emicizumab have changed the treatment landscape of haemophilia A, including preventing bleeding in patients with CHwI. However, rFVIIa will continue to play a significant role in the treatment of such patients, particularly during breakthrough bleeding or surgical procedures.
- |||||||||| SS109 / Gensciences
Trial completion: SS109 and NovoSeven (clinicaltrials.gov) - Jul 19, 2024
P1/2, N=24, Completed,
However, rFVIIa will continue to play a significant role in the treatment of such patients, particularly during breakthrough bleeding or surgical procedures. Recruiting --> Completed
- |||||||||| SS109 / Gensciences
Trial primary completion date: SS109 and NovoSeven (clinicaltrials.gov) - Mar 2, 2024
P1/2, N=24, Recruiting,
Emicizumab concentrations are monitored by19/30 (63%) centers: 9 every 3-6 months, 4 annually, 1 Trial primary completion date: Jan 2024 --> May 2024
- |||||||||| Acquired Hemophilia A: A Rare Cause of Uncontrolled Hemorrhage in the Intensive Care Unit (San Diego Convention Center, Room 31A-C (Upper Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_7261;
Although rare, a high index of suspicion for AHA should remain for actively bleeding patients with a prolonged PTT, especially in elderly patients without family history of bleeding diathesis. Early recognition of AHA allows for consultation with a hematologist and prompt initiation of treatment to restore hemostasis and prevent the morbid consequences of this condition.
- |||||||||| NovoSeven (eptacog alfa) / Novo Nordisk, Rituxan (rituximab) / Roche
Plastic Surgery Gone Wrong: Catastrophic Post-operative Hemorrhagic Shock Due to Newly Acquired Factor VIII Inhibitor (San Diego Convention Center, Area E (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_3570;
She also received factor VII product (NovoSeven) repletion to bypass the inhibited coagulation pathway to attempt to synthesize adequate coagulation factors...Her hospital course was further complicated by the development of vancomycin-resistant enterococcus (VRE) bacteremia and Acinetobacter pneumonia...In our case, the factor inhibitor level responded only minimally despite all immune therapies. Early detection of this phenomenon in instances of unexplained hemorrhagic shock and ideally prior to surgery is necessary to rapidly suppress inhibitor levels before the development of catastrophic sequelae, as seen in our patient.
- |||||||||| Sevenfact (eptacog beta activated) / LFB SA, HEMA Biologics
Review, Journal: Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective. (Pubmed Central) - Feb 6, 2024
In this review, we summarise current data regarding the mode of action, clinical efficacy and safety of eptacog beta for the management of haemophilia A and B in patients with inhibitors from a European perspective. In addition to providing a valuable summary of the analyses of the clinical data for eptacog beta conducted for the EMA, our review summarises the potential differentiators for eptacog beta compared with other current bypassing agents.
|
